152 extractive question-and-answer pairs built from Consensus Document, published by icmr.gov.in. Every answer is a verbatim span of text the source prints, and each row carries the passage it sits in, its offset in that passage, the source quote, the page and the location in the document, so any row can be checked against the original. 97 of the 152 pairs (63.8%) are explanatory questions and 55 restate a figure. 100.00% of rows pass the corpus quality gate.
Use the API URL with your free DD token in notebooks, scripts, and pipelines.
https://www.desidata.in/api/datasets/consensus-document-on-breast-cancer-question-and-answer-dataset/downloadDataset downloads are free. For Python or API downloads, sign in once and create a free DD token; set it as DD_TOKEN or save it in your notebook's secrets. Requests are linked to your account so your download history and counts stay accurate.
# One-time install: pip install desidata
# Set DD_TOKEN in your environment first (create a free token in Profile & settings).
import desidata
df = desidata.load("consensus-document-on-breast-cancer-question-and-answer-dataset")
df.head()Sign in with Google to download.
Usable for analysis, but expect some cleaning before you rely on it.
Consensus Document on Management of Pancreatic Cancer - Question and Answer Dataset
Economy · 268 rows
ICMR Standard Treatment Workflow for Cataract - Question and Answer Dataset
Economy · 27 rows
Neurology Questions from P a R T N E R S - Question and Answer Dataset
Economy · 107 rows
Beginner's Guide for Systematic Reviews - Question and Answer Dataset
Economy · 407 rows
Annual Report 2015-16 by agriwelfare.gov.in - Question and Answer Dataset
Economy · 1,013 rows
Higher Education in India - Question and Answer Dataset
Economy · 1,594 rows
Gender Policy of NABARD - Question and Answer Dataset
Economy · 14 rows
ICAR Annual Report 2025-26 - Question and Answer Dataset
Economy · 1,101 rows
First 10 of 152 rows
| question | answer | context | answer_start | question_type | knowledge_quality_score | source_quote | source_page | source_location | confidence | validation_status |
|---|---|---|---|---|---|---|---|---|---|---|
| What factors determine the success of the breast conservation approach? | satisfactory cosmetic outcome and the probability of tumor control or late sequelae are not inferior to mastectomy | 21 Consensus Document for Management of Breast Cancer 1-3 +ve nodes, it is being increasingly considered as discussed later. Accelerated Partial Breast Irradiation (APBI) with various techniques is an option for highly select cases in experienced centres. RT indications and dose regimes are described later. *Eligibility for BCT: The breast conservation approach would be considered successful if it produces satisfactory cosmetic outcome and the probability of tumor control or late sequelae are not inferior to mastectomy. | 411 | definition | 1.000 | *Eligibility for BCT: The breast conservation approach would be considered successful if it produces satisfactory cosmetic outcome and the probability of tumor control or late sequelae are not inferior to mastectomy. | 22 | page=22,block=0 | 0.700 | valid |
| What is essential for the effective treatment of breast cancers? | standardized histopathology evaluation and reporting | 24 Consensus Document for Management of Breast Cancer Optimal management of breast cancers hinges upon standardized histopathology evaluation and reporting30 . All specimens should be transported to the pathology lab immediately. In case a delay is expected surgeons should slice specimen’s posterior aspect upwards. All lumpectomies should be treated as potentially harboring cancer and should be oriented for margin evaluation. A six surface margin (anterior, posterior, inferior, superior, medial and lateral) is sufficient for routine evaluation though more extensive sampling may result in greater margin positivity. Close margins are to be evaluated radially whereas shave margins should be evaluated for further margins. All specimens should be fixed in 10% neutral buffered formalin with pH7.2 to 7.4. | 104 | definition | 1.000 | 24 Consensus Document for Management of Breast Cancer Optimal management of breast cancers hinges upon standardized histopathology evaluation and reporting30 . | 25 | page=25,block=0 | 0.700 | valid |
| What is the main objective of managing metastatic breast cancer? | to allow the patient to regain and maintain the best possible quality of life and to prolong her life to the extent possible | he metastatic disease may be symptomatic or asymptomatic and detected at initial presentation or during follow up. The overarching goal of managing metastatic breast cancer is to allow the patient to regain and maintain the best possible quality of life and to prolong her life to the extent possible. This requires careful assessment and documentation of cancer associated symptoms, previous treatment history along with the nature, extent and tempo of loco-regional and metastatic disease. In addition to assessing prognostic and predictive factors like ER/PR and HER2neu, patient’s physiological, psychological and financial reserve and support system should also be assessed. This helps in providing individualized holistic care which could range from intensive chemotherapy to only best supportive care, in consultation with the patient and the family. | 176 | definition | 1.000 | The overarching goal of managing metastatic breast cancer is to allow the patient to regain and maintain the best possible quality of life and to prolong her life to the extent possible. | 33 | page=33,block=2 | ||
| What is Optimal mammographic evaluation? | not possible due to breast reconstruction or implants | d. Optimal mammographic evaluation is not possible due to breast reconstruction or implants. | 38 | definition | 0.980 | Optimal mammographic evaluation is not possible due to breast reconstruction or implants. | 19 | page=19,block=0 | 0.850 | valid |
| Why is breast MRI useful in expert centers when mammography is sub-optimal? | dense breast (as in some young women) or prior breast reconstruction | OBC LOBC/LABC MBC Purpose/ Comments RoutineTests (CBC, Biochemistry) YES YES YES To assess fitness for anesthesia & chemotherapy Breast Imaging (see flow chart) YES YES *In selected cases where it is clinically indicated B/LMammography: If the breast lump is suspected to be malignant, especially if BCT is being considered. USG: If cystic/ benign lesion is suspected, especially in young women MRI: In expert centres breast MRI is useful in screening or characterizing breast lump if mammography is sub-optimal due to dense breast (as in some young women) or prior breast reconstruction. Specially useful for screening young women at high risk of developing breast cancer due to family history or BRCA mutation Cytological/ Histopathological Confirmation of diagnosis YES YES YES Core biopsy: Preferred method in all cases and mandatory if Neo- adjuvant systemic therapy is planned for histological grading and receptor status. | 519 | relationship | 0.970 | USG: If cystic/ benign lesion is suspected, especially in young women MRI: In expert centres breast MRI is useful in screening or characterizing breast lump if mammography is sub-optimal due to dense breast (as in some young women) or prior breast reconstruction. | ||||
| Why are high-risk women screened for breast cancer? | family history or BRCA mutation8. c | b. Screening high risk women due to family history or BRCA mutation8. c. Axillary node metastasis without clinical/mammographic evidence of breast primary. | 36 | relationship | 0.970 | Screening high risk women due to family history or BRCA mutation8. c. | 19 | page=19,block=0 | 0.800 | valid |
| Why is Ductal Carcinoma In Situ (DCIS) being increasingly diagnosed in the west? | widespread use of screening mammography | Ductal Carcinoma In Situ (DCIS) is being increasingly diagnosed in the west due to widespread use of screening mammography. The natural history of screen detected DCIS is variable and many of these will not progress and may have remained clinically silent during the women’s lifetime. | 83 | relationship | 0.970 | Ductal Carcinoma In Situ (DCIS) is being increasingly diagnosed in the west due to widespread use of screening mammography. | 20 | page=20,block=4 | 0.800 | valid |
| What risk is reduced by adjuvant treatment with Tamoxifen or radiotherapy after lumpectomy? | local recurrence of DCIS and invasive cancer24-26 | Simple mastectomy21 with or without reconstruction is performed for large or multicentric DCIS or when there is diffuse micro-calcification. Adjuvant treatment with Tamoxifen (for ER/PR +ve tumors) or Radiotherapy after lumpectomy reduces the risk of local recurrence of DCIS and invasive cancer24-26. Tamoxifen also reduces risk of contralateral DCIS and cancer. | 251 | relationship | 0.970 | Adjuvant treatment with Tamoxifen (for ER/PR +ve tumors) or Radiotherapy after lumpectomy reduces the risk of local recurrence of DCIS and invasive cancer24-26. | 21 | page=21,block=0 | 0.800 | valid |
| Why is axillary treatment commonly practiced for all node-positive cases in many Indian centers? | sub-optimal axillary surgery or histopathological evaluation in practice settings | 30 Consensus Document for Management of Breast Cancer Axilla: It is a common practice in many Indian centres to treat axilla for all node +ve cases, possibly due to sub-optimal axillary surgery or histopathological evaluation in practice settings. As post-op axillary RT can increase arm & shoulder morbidity, it is advocated for residual axillary disease or node +ve after inadequate axillary surgery and revision surgery is not being considered for various reasons. | 166 | relationship | 0.970 | 30 Consensus Document for Management of Breast Cancer Axilla: It is a common practice in many Indian centres to treat axilla for all node +ve cases, possibly due to sub-optimal axillary surgery or histopathological evaluation in practice settings. | 31 | page=31,block=0 | 0.800 | valid |
| What is the impact of a longer duration of chemotherapy for metastatic breast cancer? | modest improvement •• in overall and progression free survival | **Chemotherapy52-55,58 Combination chemotherapy is preferred in patients with high visceral burden and in other cases •• single agents can be used. Longer duration of chemotherapy for metastatic breast cancer is associated with modest improvement •• in overall and progression free survival. Chemotherapy duration should be individualized. | 228 | relationship | 0.970 | Longer duration of chemotherapy for metastatic breast cancer is associated with modest improvement •• in overall and progression free survival. | 34 | page=34,block=3 | 0.800 | valid |
Read straight from the file — download or use the API URL for the full dataset.
| 0.700 |
| valid |
| 17 |
| page=17,block=2 |
| 0.800 |
| valid |